# EDGAR Filing Document

**Accession Number:** 0000894158
**File Stem:** 0001104659-25-117211
**Filing Date:** 2025-12
**Character Count:** 2917
**Document Hash:** 4a6f7c914d718984a7dd7944eed026a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-117211.hdr.sgml**: 20260407

**ACCESSION NUMBER**: 0001104659-25-117211

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Theriva Biologics, Inc.
- **CENTRAL INDEX KEY:** 0000894158
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 133808303
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 9605 MEDICAL CENTER DRIVE
- **STREET 2:** SUITE 270
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** (734) 332-7800

**MAIL ADDRESS:**
- **STREET 1:** 9605 MEDICAL CENTER DRIVE
- **STREET 2:** SUITE 270
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Synthetic Biologics, Inc.
- **DATE OF NAME CHANGE:** 20120305

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADEONA PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20081027

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PIPEX PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20061214

![Theriva Biologics Inc.: Theriva ...](image_001.jpg)

December 1, 2025

***<u>VIA EDGAR</u>***

United States Securities and Exchange Commission<br> Division of Corporation Finance<br> 100 F Street, N.E.<br> Washington, D.C. 20549<br> Attention: Doris Gama

Re: Theriva Biologics, Inc.<br> Registration Statement on Form S-3<br> Filed November 7, 2025<br> File No: 333-291381

Dear Ms. Gama:

Theriva Biologics, Inc. (the "**Registrant**") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-291381), be accelerated by the U.S. Securities and Exchange Commission (the "**Commission**") to become effective on **Tuesday, December 2, 2025**, at **9:00 a.m**., Eastern Time, or as soon as reasonably practicable thereafter.

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| THERIVA BIOLOGICS, INC. | THERIVA BIOLOGICS, INC. |
| By: | /s/ Steven A. Shallcross |
| Name: | Steven A. Shallcross |
| Title: | Chief Executive Officer and |
|  | Chief Financial Officer |

---

cc: Leslie Marlow, Blank Rome LLP